Go Pro
→ Buy this stock today (From Chaikin Analytics) (Ad)tc pixel Free ACIU Stock Alerts

AC Immune (ACIU) Financials

AC Immune logo
$2.20 +0.02 (+0.92%)
Closing price 07/17/2026 04:00 PM Eastern
Extended Trading
$2.26 +0.05 (+2.50%)
As of 07/17/2026 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for AC Immune

Annual Income Statements for AC Immune

This table shows AC Immune's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 20 -6.97 -27 -52 47 -70 -80 -77 -65 -56
Consolidated Net Income / (Loss)		 20 -6.97 -27 -52 47 -70 -80 -77 -65 -56
Net Income / (Loss) Continuing Operations		 20 -6.97 -27 -52 47 -70 -80 -77 -65 -56
Total Pre-Tax Income 		20 -6.97 -27 -52 47 -70 -80 -77 -65 -56
Total Operating Income		 19 -10 -23 -50 46 -69 -86 -77 -64 -58
Total Gross Profit		 39 23 21 7.03 114 17 0.00 4.26 18 30
Total Revenue		 39 23 21 7.03 114 17 0.00 4.26 18 30
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 20 33 44 57 68 87 86 81 81 88
Selling, General & Admin Expense		 3.42 7.75 10 13 17 21 20 17 18 19
Research & Development Expense		 17 25 34 45 52 67 68 65 65 69
Other Operating Expenses / (Income)		 - - - -0.29 -0.59 -1.53 -1.29 -1.45 -1.77 -0.16
Total Other Income / (Expense), net		 1.65 3.30 -3.97 -1.42 0.94 -0.75 6.58 0.12 -0.71 1.62
Interest Expense		 -0.06 -0.04 -0.19 0.34 1.99 0.21 0.64 0.38 0.21 0.15
Interest & Investment Income		 1.59 3.26 - 0.13 0.31 0.09 7.09 0.07 1.24 3.52
Other Income / (Expense), net		 - - -4.16 -1.21 2.61 -0.63 0.12 0.43 -1.75 -1.76
Income Tax Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.00
Basic Earnings per Share		 $0.47 ($0.14) ($0.46) ($0.82) $0.64 ($0.86) ($0.97) ($0.92) ($0.76) ($0.56)
Weighted Average Basic Shares Outstanding		 43.41M 50.10M 58.58M 67.56M 71.86M 71.94M 83.48M 83.62M 99.20M 100.41M
Diluted Earnings per Share		 $0.44 ($0.14) ($0.46) ($0.82) $0.64 ($0.86) ($0.97) ($0.92) ($0.76) ($0.56)
Weighted Average Diluted Shares Outstanding		 46.04M 50.10M 58.58M 67.56M 71.86M 71.94M 83.48M 83.62M 99.20M 100.41M
Weighted Average Basic & Diluted Shares Outstanding		 43.41M 50.10M 58.58M 67.56M 71.86M 71.94M 83.48M 83.62M 99.20M 100.41M

Quarterly Income Statements for AC Immune

No quarterly income statements for AC Immune are available.

Annual Cash Flow Statements for AC Immune

This table details how cash moves in and out of AC Immune's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 72 71 -24 34 107 -63 -86 -82 58 -45
Net Cash From Operating Activities		 -44 -5.54 -23 -45 107 -67 -147 -80 -72 -47
Net Cash From Continuing Operating Activities		 44 -5.54 -23 -45 107 -60 -147 -80 7.66 -47
Net Income / (Loss) Continuing Operations		 20 -6.97 -27 -52 47 -70 -80 -77 -65 -56
Consolidated Net Income / (Loss)		 20 -6.97 -27 -52 47 -70 -80 -77 -65 -56
Depreciation Expense		 0.29 0.27 0.60 0.98 1.32 2.22 2.63 2.55 2.64 2.38
Non-Cash Adjustments To Reconcile Net Income		 -1.42 -1.84 6.23 4.17 59 5.64 -76 1.59 85 -110
Changes in Operating Assets and Liabilities, net		 25 2.99 -2.40 1.84 - 1.58 6.93 -7.74 -15 116
Net Cash From Investing Activities		 -0.24 -0.88 -1.89 -33 0.00 32 -2.88 26 78 -0.64
Net Cash From Continuing Investing Activities		 -0.24 -0.88 -1.89 -33 0.00 -1.96 -2.88 -1.34 -0.95 -0.64
Purchase of Property, Plant & Equipment		 -0.24 -0.88 -1.85 -1.89 - -1.93 -2.88 -1.34 -0.95 -0.64
Net Cash From Financing Activities		 28 77 0.28 111 0.00 -0.91 45 -1.46 51 0.12
Net Cash From Continuing Financing Activities		 28 77 0.28 111 0.00 -0.91 45 -0.62 51 0.12
Issuance of Common Equity		 0.08 -3.73 0.07 0.01 - 0.16 19 - 52 0.12
Cash Interest Paid		 - - - - - - 0.51 - - 0.12
Cash Interest Received		 - - - - - - 0.00 - 0.71 1.72

Quarterly Cash Flow Statements for AC Immune

No quarterly cash flow statements for AC Immune are available.

Annual Balance Sheets for AC Immune

This table presents AC Immune's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 153 135 200 309 270 286 201 218 255
Total Current Assets		 151 132 196 303 262 222 139 149 190
Cash & Equivalents		 149 128 159 200 182 90 34 93 40
Restricted Cash		 - - - - - 0.40 0.39 0.43 0.46
Accounts Receivable		 - 0.00 0.20 - - 1.53 0.87 19 2.43
Prepaid Expenses		 1.25 1.48 2.40 2.88 4.46 3.30 5.09 7.66 4.74
Other Current Assets		 0.87 2.87 3.73 1.13 1.80 127 98 29 142
Plant, Property, & Equipment, net		 1.10 2.41 3.38 4.05 4.99 5.59 4.61 4.02 2.92
Plant, Property & Equipment, gross		 1.10 2.41 3.38 4.05 4.99 5.59 4.61 4.02 2.92
Total Noncurrent Assets		 0.08 0.13 0.31 2.65 2.89 58 58 64 62
Intangible Assets		 - - - - 0.00 55 55 60 56
Other Noncurrent Operating Assets		 0.08 0.13 0.31 2.65 2.89 3.19 3.04 4.17 6.00
Total Liabilities & Shareholders' Equity		 153 135 200 309 270 286 201 218 255
Total Liabilities		 13 16 19 28 26 32 18 26 131
Total Current Liabilities		 9.74 10 13 18 16 22 12 16 111
Accounts Payable		 3.96 1.12 2.01 0.15 2.47 2.19 1.01 2.00 2.93
Accrued Expenses		 5.27 8.52 11 12 13 18 10 13 13
Current Deferred Revenue		 0.51 0.36 - 4.63 0.35 0.78 0.64 0.16 0.00
Other Current Liabilities		 - - 0.34 1.13 0.50 0.62 0.59 0.80 95
Total Noncurrent Liabilities		 3.73 5.56 5.95 9.61 10 10 5.91 10 20
Capital Lease Obligations		 - - 0.00 1.87 2.01 2.56 2.44 3.36 4.85
Noncurrent Employee Benefit Liabilities		 3.73 5.05 5.76 7.74 8.43 7.76 3.48 6.86 9.75
Other Noncurrent Operating Liabilities		 - 0.51 0.19 - - - - 0.00 5.03
Total Equity & Noncontrolling Interests		 140 120 181 282 243 254 183 191 124
Total Preferred & Common Equity		 140 120 181 282 243 254 183 191 124
Preferred Stock		 - 193 303 358 392 472 467 565 528
Total Common Equity		 140 -73 -122 -77 -148 -218 -284 -374 -404
Common Stock		 1.11 1.18 1.37 1.49 1.74 1.96 1.94 2.49 2.45
Retained Earnings		 - - -124 -78 -150 -220 -286 -376 -406
Treasury Stock		 - - - 0.00 -0.11 -0.14 -0.13 -0.12 -0.24
Other Equity Adjustments		 139 -75 - - - 0.00 0.01 -0.06 -0.01

Quarterly Balance Sheets for AC Immune

No quarterly balance sheets for AC Immune are available.

Annual Metrics And Ratios for AC Immune

This table displays calculated financial ratios and metrics derived from AC Immune's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% -41.71% -8.81% -66.20% 1,525.70% -84.74% -100.00% 0.00% 313.55% 71.02%
EBITDA Growth		 0.00% -152.83% -167.13% -89.54% 198.78% -235.21% -23.76% 11.89% 14.63% 9.17%
EBIT Growth		 0.00% -155.11% -165.82% -88.99% 194.36% -243.43% -23.59% 11.62% 14.03% 9.19%
NOPAT Growth		 0.00% -138.58% -125.29% -117.74% 230.62% -205.15% -24.89% 11.25% 16.78% 9.47%
Net Income Growth		 0.00% -134.36% -288.99% -91.07% 190.73% -248.81% -14.15% 4.07% 15.72% 12.98%
EPS Growth		 0.00% -131.82% -228.57% -78.26% 178.05% -234.38% -12.79% 5.18% 17.21% 26.15%
Operating Cash Flow Growth		 0.00% 87.43% -308.98% -97.60% 338.66% -162.86% -118.12% 45.69% 9.72% 33.99%
Free Cash Flow Firm Growth		 0.00% 0.00% -694.45% -98.41% 249.20% -202.14% -342.63% 83.72% 114.05% -617.09%
Invested Capital Growth		 0.00% 0.00% 14.59% -2.18% -70.67% 33.11% 1,739.14% -9.14% -33.22% -12.39%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 100.00% 100.00% 100.00%
EBITDA Margin		 48.38% -43.84% -128.43% -720.24% 43.76% -387.84% 0.00% -1,730.50% -357.25% -189.73%
Operating Margin		 47.64% -45.04% -111.28% -716.87% 40.32% -396.99% 0.00% -1,800.43% -362.30% -191.80%
EBIT Margin		 47.64% -45.04% -131.30% -734.14% 42.61% -400.59% 0.00% -1,790.44% -372.21% -197.65%
Profit (Net Income) Margin		 51.85% -30.57% -130.39% -737.14% 41.14% -401.28% 0.00% -1,798.04% -366.41% -186.44%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.02% 100.02% 100.01%
Interest Burden Percent		 108.84% 67.87% 99.31% 100.41% 96.55% 100.17% 92.52% 100.41% 98.42% 94.33%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -33.90% -35.53% -42.82%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4.31% -3.12% -17.88%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1.18% 1.02% 7.16%
Return on Equity (ROE)		 0.00% -4.98% -20.87% -34.47% 20.33% -26.64% -32.12% -35.08% -34.51% -35.66%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -142.55% -24.31% 4.30% -29.61%
Operating Return on Assets (OROA)		 0.00% -6.70% -18.90% -30.77% 19.11% -24.11% 0.00% -31.31% -31.31% -25.21%
Return on Assets (ROA)		 0.00% -4.55% -18.77% -30.89% 18.46% -24.15% 0.00% -31.44% -30.82% -23.78%
Return on Common Equity (ROCE)		 0.00% -4.98% -5.34% 22.47% -8.76% 11.41% 23.67% 40.32% 60.69% 88.06%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -4.98% -22.60% -28.68% 16.68% -28.74% -31.47% -41.87% -33.76% -45.35%
Net Operating Profit after Tax (NOPAT)		 19 -7.19 -16 -35 46 -48 -60 -54 -45 -40
NOPAT Margin		 47.64% -31.53% -77.89% -501.81% 40.32% -277.90% 0.00% -1,260.30% -253.61% -134.26%
Net Nonoperating Expense Percent (NNEP)		 0.00% 0.29% -7.84% -10.40% 0.39% -7.81% -11.34% -38.21% -32.41% -24.93%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -28.96% -22.96% -31.43%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 8.74% 34.01% 50.02% 180.37% 14.54% 120.26% 0.00% 401.25% 103.41% 63.20%
R&D to Revenue		 43.61% 111.03% 161.26% 640.58% 45.66% 385.50% 0.00% 1,533.32% 368.93% 229.12%
Operating Expenses to Revenue		 52.36% 145.04% 211.28% 816.87% 59.68% 496.99% 0.00% 1,900.43% 462.30% 291.80%
Earnings before Interest and Taxes (EBIT)		 19 -10 -27 -52 49 -70 -86 -76 -66 -60
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 19 -9.99 -27 -51 50 -68 -84 -74 -63 -57
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 77.15 5.04 21.32 0.00 39.99 23.74 8.89
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 12.25 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 8.16% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 4.46 4.01 8.87 8.62
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 93.36 5.58 29.28 0.00 142.06 50.69 25.23
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 12.75 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 13.10 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 13.84 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 5.96 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 12.18 0.00 0.00 0.00 165.06 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.02 0.04
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.02 0.04
Financial Leverage		 0.00 -1.07 -1.07 -1.06 -1.05 -1.05 -0.69 -0.27 -0.33 -0.40
Leverage Ratio		 0.00 1.10 1.11 1.12 1.10 1.10 1.12 1.12 1.12 1.50
Compound Leverage Factor		 0.00 0.74 1.10 1.12 1.06 1.10 1.03 1.12 1.10 1.41
Debt to Total Capital		 0.00% 0.00% 0.00% 0.20% 0.66% 0.82% 1.00% 1.32% 1.73% 3.77%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.20% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.66% 0.82% 1.00% 1.32% 1.73% 3.77%
Preferred Equity to Total Capital		 0.00% 0.00% 161.16% 167.52% 126.35% 159.67% 184.04% 251.88% 290.52% 410.13%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 100.00% -61.16% -67.72% -27.01% -60.49% -85.04% -153.19% -192.25% -313.90%
Debt to EBITDA		 0.00 0.00 0.00 -0.01 0.04 -0.03 -0.03 -0.03 -0.05 -0.08
Net Debt to EBITDA		 0.00 0.00 0.00 3.74 -5.93 3.74 1.05 0.44 1.44 0.62
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.04 -0.03 -0.03 -0.03 -0.05 -0.08
Debt to NOPAT		 0.00 0.00 0.00 -0.01 0.04 -0.04 -0.04 -0.05 -0.08 -0.12
Net Debt to NOPAT		 0.00 0.00 0.00 5.37 -6.44 5.23 1.45 0.60 2.03 0.88
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.04 -0.04 -0.04 -0.05 -0.08 -0.12
Altman Z-Score		 0.00 0.00 0.00 16.31 14.10 8.01 5.40 3.11 6.91 -1.29
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 74.41% 165.18% 143.07% 142.85% 173.70% 214.95% 275.88% 346.96%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.00 15.47 13.19 14.75 16.72 16.53 10.12 11.16 9.22 1.71
Quick Ratio		 0.00 15.34 12.75 14.27 16.48 16.11 4.18 2.82 6.94 0.38
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 2.97 -18 -35 52 -53 -237 -38 5.41 -28
Operating Cash Flow to CapEx		 -18,067.25% -628.03% -1,226.08% -2,372.34% 0.00% -3,488.69% -5,087.86% -5,937.69% -7,541.57% -7,468.75%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 -103.29 26.27 -257.17 -372.30 -100.21 25.83 -190.66
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 -131.97 53.69 -323.46 -230.75 -207.23 -343.23 -323.46
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 -137.53 53.69 -332.73 -235.28 -210.72 -347.78 -327.79
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.15 0.14 0.04 0.45 0.06 0.00 0.02 0.08 0.13
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.55 1.81 2.86
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 20.73 11.83 2.43 30.75 3.86 0.00 0.83 4.08 8.68
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 102.85 202.16 127.69
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 102.85 202.16 127.69
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 -10 -8.68 -8.87 -15 -10 166 151 101 88
Invested Capital Turnover		 0.00 -4.49 -2.21 -0.80 -9.52 -1.38 0.00 0.03 0.14 0.32
Increase / (Decrease) in Invested Capital		 0.00 -10 1.48 -0.19 -6.27 5.01 176 -15 -50 -12
Enterprise Value (EV)		 0.00 0.00 0.00 656 637 510 740 605 893 760
Market Capitalization		 0.00 0.00 0.00 542 576 372 356 170 418 268
Book Value per Share		 $0.00 $2.79 ($1.25) ($2.14) ($1.13) ($2.06) ($3.03) ($3.40) ($4.47) ($4.07)
Tangible Book Value per Share		 $0.00 $2.79 ($1.25) ($2.14) ($1.13) ($2.06) ($3.80) ($4.05) ($5.19) ($4.63)
Total Capital		 0.00 140 120 181 284 245 256 185 194 129
Total Debt		 0.00 0.00 0.00 0.36 1.87 2.01 2.56 2.44 3.36 4.85
Total Long-Term Debt		 0.00 0.00 0.00 0.00 1.87 2.01 2.56 2.44 3.36 4.85
Net Debt		 0.00 -149 -128 -189 -297 -253 -88 -32 -90 -36
Capital Expenditures (CapEx)		 0.24 0.88 1.85 1.89 0.00 1.93 2.88 1.34 0.95 0.64
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -8.49 -5.66 -6.37 -14 -9.20 109 92 39 38
Debt-free Net Working Capital (DFNWC)		 0.00 141 122 183 285 246 200 126 133 78
Net Working Capital (NWC)		 0.00 141 122 183 285 246 200 126 133 78
Net Nonoperating Expense (NNE)		 -1.65 -0.22 11 17 -0.94 21 19 23 20 16
Net Nonoperating Obligations (NNO)		 0.00 -150 -129 -189 -297 -253 -88 -32 -90 -36
Total Depreciation and Amortization (D&A)		 0.29 0.27 0.60 0.98 1.32 2.22 2.63 2.55 2.64 2.38
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -37.24% -27.23% -90.64% -12.06% -52.78% 0.00% 2,151.61% 221.08% 126.21%
Debt-free Net Working Capital to Revenue		 0.00% 618.45% 586.83% 2,607.02% 249.21% 1,411.11% 0.00% 2,963.48% 753.85% 260.56%
Net Working Capital to Revenue		 0.00% 618.45% 586.83% 2,601.94% 249.21% 1,411.11% 0.00% 2,963.48% 753.85% 260.56%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($0.46) $0.00 $0.64 ($0.86) ($0.97) ($0.85) ($0.64) ($0.56)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 57.36M 0.00 71.86M 71.94M 83.48M 83.62M 99.20M 100.41M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($0.46) $0.00 $0.64 ($0.86) ($0.97) ($0.85) ($0.64) ($0.56)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 57.08M 0.00 71.86M 71.94M 83.48M 83.62M 99.20M 100.41M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 57.08M 0.00 71.86M 71.94M 83.48M 83.62M 99.20M 100.41M
Normalized Net Operating Profit after Tax (NOPAT)		 13 -7.19 -16 -35 32 -48 -60 -54 -45 -40
Normalized NOPAT Margin		 33.35% -31.53% -77.89% -501.81% 28.22% -277.90% 0.00% -1,260.30% -253.61% -134.26%
Pre Tax Income Margin		 51.85% -30.57% -130.39% -737.14% 41.14% -401.28% 0.00% -1,797.71% -366.35% -186.43%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 -151.93 24.44 -335.95 -135.80 -198.46 -313.02 -405.83
NOPAT to Interest Expense		 0.00 0.00 0.00 -103.85 23.12 -233.05 -95.19 -139.70 -213.28 -275.67
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 -157.49 24.44 -345.22 -140.33 -201.95 -317.57 -410.16
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 -109.41 23.12 -242.33 -99.73 -143.19 -217.83 -280.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 9.17% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for AC Immune

No quarterly metrics and ratios for AC Immune are available.


Financials Breakdown Chart

AC Immune Financials - Frequently Asked Questions

According to the most recent income statement we have on file, AC Immune's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

AC Immune's net income appears to be on an upward trend, with a most recent value of -$56.15 million in 2024, falling from $20.28 million in 2015. The previous period was -$64.52 million in 2023. See where experts think AC Immune is headed by visiting AC Immune's forecast page.

AC Immune's total operating income in 2024 was -$57.76 million, based on the following breakdown:
  • Total Gross Profit: $30.12 million
  • Total Operating Expenses: $87.88 million

Over the last 9 years, AC Immune's total revenue changed from $39.10 million in 2015 to $30.12 million in 2024, a change of -23.0%.

AC Immune's total liabilities were at $130.84 million at the end of 2024, a 396.0% increase from 2023, and a 871.3% increase since 2016.

In the past 8 years, AC Immune's cash and equivalents has ranged from $34.18 million in 2022 to $200.16 million in 2019, and is currently $40.00 million as of their latest financial filing in 2024.

Over the last 9 years, AC Immune's book value per share changed from 0.00 in 2015 to -4.07 in 2024, a change of -407.1%.


Related Companies

Financial statements for NASDAQ:ACIU last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Central banks bought 710 tonnes - this fund pays monthly
Gold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan...
Investors Alley | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Elon’s message for America
Elon Musk bought Super Bowl ad time at $266,000 per second - something he has never done before. 125 million A...
Stansberry Research | Sponsoredtc pixel
This same-day trade is getting a lot of attention
Zero-days-to-expiration trades happen every single day - and most traders either ignore them or use them wrong...
Base Camp Trading | Sponsoredtc pixel
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...
Banyan Hill Publishing | Sponsoredtc pixel
3 AI stocks to buy before August 2026
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
The only metrics you should watch as a day trader.
Day traders and swing traders don't need the same metrics - and using the wrong ones costs you edge. After 40 ...
The TradingPub | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel